Zovirax (acyclovir)
Last reviewed · Source: First Databank (FDB) drug data
Overview
Acyclovir, a synthetic purine nucleoside analog derived from guanine, has antiviral activity in vitro against various Herpesviridae including herpes simplex virus types 1 and 2 (HSV-1 and HSV-2).
Acyclovir is used topically as a 5% cream for the treatment of recurrent herpes labialis (perioral herpes, cold sores, fever blisters) in immunocompetent individuals. Acyclovir is used topically as a 5% ointment in the treatment of limited, non-life-threatening, mucocutaneous herpes simplex virus (HSV-1 and HSV-2) infections in immunocompromised individuals. The manufacturer states that acyclovir ointment may be used topically for the management of initial genital herpes; however, topical therapy is not usually recommended for the treatment of genital herpes.
There is no evidence that topical acyclovir will either prevent transmission of HSV infections to other individuals or prevent recurrent HSV infections when applied in the absence of signs and symptoms of infection. Acyclovir should not be used topically for prevention of recurrent HSV infections.
Generic name: acyclovir
Pronunciation: (ay-SYE-kloe-vir)
Reference product & biosimilars
No reference, biosimilar or interchangeable associated with this drug.
Today’s intelligence on Zovirax
Indications
The following indications are listed for Zovirax:
- Recurrent Herpes Simplex Labialis
Also known as: Recurrent Herpes Labialis, Recurrent Hsv Type 1 Infection Of The Lip Or Nares.
Dosing
No dosing information is available for this tab.
Acyclovir 5% cream is applied topically to affected areas of the lips and surrounding skin. The cream should not be applied to the eye, inside the mouth or nose, or to mucous membranes.
Acyclovir 5% ointment is applied topically to the skin. The ointment should not be applied to the eye. A finger cot or rubber glove should be used when applying the ointment to prevent autoinoculation of other sites and transmission of the virus to other individuals.
No dosing information is available for this tab.
No dosing information is available for this tab.
Drug interactions
Because systemic absorption appears to be minimal following topical application of acyclovir, drug interactions between topical acyclovir and systemically administered drugs is unlikely. The manufacturer states that drug interactions in patients receiving topical acyclovir concurrently with other topical or systemic drugs have not been reported to date.
There are no contraindication interactions for this drug.
There are no severe interactions for this drug.
There are no moderate interactions for this drug.
Contraindications
There is no enhanced messaging for this drug.
There are no contraindication contraindications for this drug.
There are no severe contraindications for this drug.
There are no moderate contraindications for this drug.
Adverse reactions
There is no enhanced messaging for this drug.
There are no severe adverse reactions for this drug.
There are no less severe adverse reactions for this drug.
Precautions
No enhanced messaging available.
No enhanced messaging available.
Acyclovir has not been shown to be teratogenic in standard tests following subcutaneous administration in rats and rabbits, IV administration in rabbits, and oral administration in mice. However, in nonstandard tests in rats, fetal abnormalities, principally involving the head and tail, were observed at higher subcutaneous acyclovir dosages, which also were associated with maternal toxicity. The drug crosses the placenta in humans following oral or IV administration. There are no adequate and controlled studies to date using acyclovir in pregnant women, and the drug should be used during pregnancy only when the potential benefits justify the possible risks to the fetus.
Although it is not known whether acyclovir is distributed into milk following topical application, the drug is distributed into milk following oral or IV administration. Following oral administration of acyclovir in 2 nursing women, milk acyclovir concentrations were 0.6-4.1 times the simultaneous maternal plasma drug concentrations. Therefore, acyclovir ointment and cream should be used with caution in nursing women. Women who have active herpetic lesions near or on the breast should avoid nursing.
No enhanced messaging available.
ICD codes
No ICD codes are available for this drug.
Formulary status
Search health-plan coverage for this drug by ZIP code.
Choose the first character of a health plan name.
Last reviewed · Source: First Databank (FDB) drug data
On this page
Actions
Sign in to save favorites
Saving this drug requires a free Physicians Office Resource account.